Article

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 years

2021-06-01

Abstract excerpt

<h4>Background</h4> We investigated the safety and immunogenicity of two recombinant COVID-19 DNA vaccine candidates in first-in-human trials. GX-19 contains plasmid DNA encoding SARS-CoV-2 spike protein, and GX-19N contains plasmid DNA encoding SARS-CoV-2 receptor binding domain (RBD) foldon and nucleocapsid protein (NP) as well as plasmid DNA encoding SARS-CoV-2 spike protein. <h4>Methods</h4> Two open-label pha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c4b3520a-2cbf-52e9-ab37-370d6c9c739f
DOI: 10.1101/2021.05.26.21257700

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsDOI 10.1101/2021.05.26.21257700Read

Rapid development of a synthetic DNA vaccine for COVID-19Semantic proximity Read

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trialSemantic proximity Read

COVID-19 and COVID-19 Vaccine in Japan—A Review from a General Physician's PerspectiveSemantic proximity Read

COVID-19 vaccinations: The unknowns, challenges, and hopes.Semantic proximity Read

COVID-19 Vaccines: Where Do We Stand at the End of 2023?Semantic proximity Read

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmissionSemantic proximity Read

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in RussiaSemantic proximity Read

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 TrialSemantic proximity Read

The COVID-19 pandemic: viral variants and vaccine efficacySemantic proximity Read

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03Semantic proximity Read